)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Candel Therapeutics (CADL) investor relations material
Candel Therapeutics R&D Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.R&D Day 2025 summary5 Dec, 2025
Pipeline overview and program updates
CAN-2409 is the lead asset, positioned as a pan-solid tumor immunotherapy with positive phase III data in localized prostate cancer, over 1,000 patients dosed, and promising results in pancreatic and non-small cell lung cancers.
CAN-3110, a next-generation replication-competent oncolytic HSV, shows encouraging survival and immune activation in recurrent high-grade glioma, with potential for broader application in nestin-expressing tumors.
R&D Day will feature updates on viral immunotherapy platforms and the oncology pipeline, including CAN-2409 and CAN-3110.
Financially, $87M in cash and a $130M term loan provide runway into Q1 2027, supporting ongoing and future trials.
Clinical trial data and development milestones
CAN-2409 met its primary endpoint in a 745-patient phase III prostate cancer trial, showing a 30% reduction in disease recurrence and strong secondary endpoint support.
CAN-2409 completed phase 2a trials in NSCLC and PDAC, and a pivotal phase 3 trial in localized prostate cancer under FDA Special Protocol Assessment.
CAN-3110 demonstrated improved median overall survival in recurrent glioblastoma compared to historical controls, with initial results published in Nature and ongoing studies exploring multiple injections and immune biomarkers.
Updated clinical data for non-small cell lung cancer and prostate cancer are expected in the next two quarters, with a pivotal phase III lung cancer trial to start in Q2 next year.
R&D strategy and innovation priorities
enLIGHTEN Discovery Platform leverages HSV-based technology and advanced analytics to create new viral immunotherapies for solid tumors.
Emphasis on experimental medicine trials to rapidly assess efficacy and inform larger studies.
Deep biomarker research and integration of precision/stratified medicine approaches guide future trial design and potential label expansion.
Focus on combination therapies and early disease intervention, leveraging immunogenic cell death and in situ vaccination concepts.
What is the timeline for CAN-2409 BLA submission?
Key pre-commercialization strategies for CAN-2409
What data supports CAN-3110 mOS improvement?
Impact of FDA's comparability agreement on BLA
Rationale for Candel's adaptive commercialization
Implications of NSCLC OS and abscopal effect
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Candel Therapeutics earnings date
Q4 202513 Mar, 2026
Next Candel Therapeutics earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer treatment. The company’s approach involves using genetically modified viruses to induce immunogenic cell death in cancer cells, which unmask tumor antigens within an activated microenvironment. This process triggers a systemic and durable immune response against tumors, acting as an in situ vaccination. Candel’s therapies are designed to potentially improve survival rates and maintain the quality of life for patients across various stages of cancer. The company is headquartered in Needham, Massachusetts, and its shares are listed on NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage